Find Academic Supervisors

• Pediatric Critical Care Medicine
• Pharmacotherapy in Critical Illness
• Neonatal Pharmacokinetics
• +3 more

Céline Thibault is a Clinical Associate Professor at the Université de Montréal's Faculty of Medicine, Department of Pediatrics. She specializes in pediatric critical care medicine with a focus on pharmacotherapy optimization in critically ill children. Her work spans neonatal pharmacokinetics, extracorporeal membrane oxygenation (ECMO), and drug dosing strategies in pediatric intensive care units. Her research integrates clinical practice and translational medicine, addressing gaps in drug management for vulnerable populations. Key projects include optimizing β-lactam antibiotic regimens and studying vasoactive agent usage in shock scenarios. She leads collaborative initiatives such as the Regroupement en intelligence artificielle appliquée aux soins aigus de l'enfant , exploring AI applications for acute pediatric care. Dr. Thibault has secured funding from the Fondation de l'Hôpital Ste-Justine and Fonds de recherche du Québec - Santé (FRQS), supporting studies on ECMO pharmacokinetics and post-intensive care outcomes. Her work bridges clinical research with bedside practice, emphasizing patient-centered approaches to medication management. Key Projects: Lead investigator for Optimisation des traitements pharmacologiques chez les enfants atteints de sepsis (2021-2024) Co-researcher in AI-driven pediatric care initiatives (2022-2026) Grants: Fondation de l'Hôpital Ste-Justine (2021-2024) FRQS - Regroupement stratégique (2022-2026) Advising: Supervised Master's student Manon Dambrun on olanzapine use in pediatric ICUs (2024) Her research emphasizes translational outcomes, including post-ICU mental health trajectories and iron deficiency in critical illness survivors. She collaborates with multidisciplinary teams to advance evidence-based pediatric critical care practices.

• Pulmonary Medicine
• Critical Care Medicine
• Pulmonary Hypertension
• +3 more

Fernando Torres, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He serves as Clinical Program Development Chief in the Division of Pulmonary and Critical Care Medicine, Medical Director of Lung Transplantation, and Head of the Pulmonary Hypertension Program. His roles include leadership in clinical development, transplant oversight, and specialty program direction. Education: Bachelor's degrees in Biology and Chemistry from Cornell University M.D. from Cornell University (Weill Cornell Medical College) Internal Medicine Residency at UT Southwestern Medical Center Fellowship in Pulmonary Disease & Critical Care Medicine at University of Colorado Denver, focusing on lung transplantation and lung volume reduction Research Interests: Dr. Torres' work focuses on critical areas impacting lung transplant recipients and pulmonary hypertension patients. Key topics include: Infectious complications following transplantation Cardiopulmonary interaction disorders Mechanisms of pulmonary arterial hypertension Genetic risk factors in PAH Novel therapeutic strategies for advanced lung disease His research has driven over 34 peer-reviewed publications and multiple clinical trials as Principal Investigator. Professional Engagement: Associate Editor of Advances in Pulmonary Hypertension Member of Texas Medical Association and International Society for Heart & Lung Transplantation Leadership roles in committees like the Solid Organ Transplant Programs Steering Committee Grants & Advising: Dr. Torres has led numerous studies funded by NIH and industry partners, with a focus on translational research bridging laboratory findings to clinical practice. His mentorship has contributed to training future generations of pulmonary critical care specialists. Labs/Teams: Oversees UT Southwestern's Pulmonary Hypertension Program and collaborates with multidisciplinary teams in lung transplantation, critical care medicine, and translational research initiatives.

• Nuclear Cardiology
• Cardiovascular Imaging
• PET Imaging
• +7 more

Sang-Geon Cho is a Visiting Assistant Professor at the Yale School of Medicine, Department of Internal Medicine. His research focuses on advanced cardiovascular imaging techniques, particularly in nuclear cardiology and PET applications. He has contributed to studies on coronary artery disease, myocardial ischemia, and cardiac amyloidosis. His work integrates artificial intelligence into medical imaging for improved diagnostic accuracy and patient prognosis. Education: Not explicitly stated in provided text. Affiliations: Yale School of Medicine, collaborating with departments such as Internal Medicine and Radiology. Research Interests: Dr. Cho specializes in translational imaging research, including: Development of AI-driven algorithms for coronary artery calcium scoring and myocardial blood flow analysis. Evaluation of PET and SPECT imaging as biomarkers for pulmonary fibrosis, cardiac amyloidosis, and thyrotoxicosis. Prognostic applications of phase analysis in heart failure and bone scintigraphy in cardiac amyloidosis. Publications: His recent work (2023-2025) emphasizes AI integration in imaging, validation of coronary stenosis models, and clinical utility of cardiac biomarkers. Key themes include optimizing imaging protocols for non-invasive diagnostics and improving risk stratification in cardiovascular diseases. Awards: No specific awards listed in the provided information. Grants/Advising: Not explicitly detailed, but his publications suggest involvement in multicenter studies and clinical trial protocols. Labs/Teams: Collaborates with the Stephen & Denise Adams Center for Parkinson’s Disease Research and other interdisciplinary teams at Yale.

• Thoracic Oncology
• Medical Imaging
• Diagnostic Imaging
• +5 more

Christopher Gange is an Assistant Professor of Radiology & Biomedical Imaging at Yale University, affiliated with the Yale School of Medicine. He serves as Fellowship Director for Thoracic Radiology and specializes in thoracic oncology imaging. His work focuses on improving diagnostic accuracy through advanced imaging technologies and machine learning applications. Education: BS in Biomedical Engineering, Boston University (2008) MMS in Medical Science, Drexel University (2008) MD in Medicine, Drexel University (2012) Radiology Residency, University of Rochester (2017) Thoracic Radiology Fellowship, Brigham and Women's Hospital (2018) Research Interests: Dr. Gange’s research integrates artificial intelligence and health informatics to optimize lung imaging techniques. He has pioneered studies on chest tomosynthesis advancements, pandemic-related imaging challenges (e.g., COVID-19), and incidental findings in lung cancer screening. Publications: His work spans over 20 peer-reviewed articles, emphasizing innovations in chest imaging, pandemic data analysis, and thoracic disease diagnostics. Key themes include machine learning for CT interpretation, pandemic-era imaging safety protocols, and standardized reporting frameworks. Advising & Grants: While no advisees are listed, his collaborative research teams include experts like Babina Gosangi and Ami Rubinowitz. He has contributed to multi-institutional studies funded by NIH and industry partnerships. Labs/Teams: Affiliated with Yale’s Cardiothoracic Imaging group and the Program for Innovation in Imaging Informatics, focusing on AI-driven radiology solutions and clinical data registries.

Xikui WangView profile

Professor

• Risk Management
• Mathematical Finance
• Dynamic Pricing
• +6 more

Dr. Xikui Wang is a Professor and Dr. L.A.H. Warren Chair in Actuarial Science at the Warren Centre for Actuarial Studies and Research within the I.H. Asper School of Business at the University of Manitoba. He joined the university in 2000, initially in the Department of Statistics before moving to his current position in 2020. Education: Ph.D. in Statistics, University of Saskatchewan (1995) M.Sc. in Mathematics, University of Saskatchewan (1989) B.Sc. in Mathematics, Central China Normal University (1984) Dr. Wang's research focuses on risk management, mathematical finance, dynamic pricing, Markov decision processes, response-adaptive clinical trials, and reinforcement learning. His work bridges theoretical statistics with practical applications in finance and healthcare. His recent publications demonstrate a consistent focus on statistical methodologies applied to healthcare (particularly Alzheimer's research and clinical trials) and financial risk management. The dominant themes include Bayesian methods, adaptive trial designs, neurostimulation therapies, and actuarial risk modeling. Dr. Wang has supervised 15 PhD and 15 Master's students. His research has been supported by multiple grants from the Natural Sciences and Engineering Research Council of Canada (NSERC), including a recent $90,000 grant for work on statistical dependence models.

Yotam Shem-TovView profile

Assistant Professor

• Labor Economics
• Public Economics
• Applied Econometrics
• +2 more

Yotam Shem-Tov is an Assistant Professor of Economics at the University of California, Los Angeles (UCLA), affiliated with the Department of Economics within the Division of Social Sciences. His research focuses on Labor and Public Economics, with a central emphasis on the U.S. criminal justice system. He holds a PhD in Economics from the University of California, Berkeley, and a BA in Economics and Philosophy from Tel-Aviv University. Shem-Tov’s research explores topics such as labor market penalties for criminal records, the effects of incarceration on employment and earnings, and the societal impacts of criminal justice policies. His work often employs applied econometric methods to analyze policy interventions and systemic disparities. Notable methodological contributions include studies on treatment effect estimation and statistical inference frameworks. His studies frequently address real-world policy questions, such as the efficacy of restorative justice programs, the long-term consequences of school discipline practices, and the economic outcomes of veterans. His findings have implications for public policy design, criminal justice reform, and socioeconomic equity.

Todd HillhouseView profile

Associate Professor

• Psychopharmacology
• Addiction Research
• Pain Research
• +3 more

Todd Hillhouse serves as Associate Professor in the Department of Psychology at the University of Wisconsin-Green Bay, affiliated with the College of Arts, Humanities and Social Sciences. His research program focuses on elucidating neurobiological mechanisms underlying addiction and pain disorders through rigorous preclinical modeling, with emphasis on developing novel therapeutic interventions. Dr. Hillhouse's educational background includes: Ph.D. from Virginia Commonwealth University M.S. from Northern Michigan University B.S. from Northern Michigan University His research interests span multiple critical domains in behavioral neuroscience: Investigation of electronic-cigarette effects on abuse liability and health risks Exploration of interactions between Major Depressive Disorder (MDD) and substance use disorders Development of non-opioid pharmacological and non-pharmacological pain treatments Mechanistic studies of ketamine, opioids, and antipsychotics in rodent models Analysis of discriminative stimulus properties and antidepressant mechanisms Analysis of his 15 most recent publications (2021-2025) reveals consistent focus on psychopharmacological mechanisms, particularly examining ketamine metabolites, opioid alternatives, and antipsychotic compounds. Key methodological approaches include discriminative stimulus assays, pain behavior models, and depression-related behavioral paradigms in rodents, with strong emphasis on translating findings to clinical applications for addiction and pain management. Scientific Awards: No specific awards or honors were documented in the provided materials. Dr. Hillhouse maintains an active undergraduate mentoring program, supervising research assistantships and independent studies focused on electronic-cigarette effects, depression-substance use interactions, and novel pain treatments. While specific grant funding sources weren't detailed, his laboratory operations and publication output indicate active research support. His laboratory currently conducts three integrated projects: (1) electronic-cigarette abuse liability assessment, (2) MDD-substance use disorder interaction modeling, and (3) development of non-opioid pain therapeutics. These projects utilize standardized behavioral pharmacology approaches including drug discrimination, pain behavior assays, and depression-related behavioral models in rodent subjects.

• Statistical Methods
• Clinical Trials
• HIV Research
• +7 more

Michael David Hughes is a Professor of Biostatistics at Harvard T.H. Chan School of Public Health, where he also serves as Director of the Center for Biostatistics in AIDS Research. His primary affiliation is with the Department of Biostatistics, and he serves as Principal Investigator of the Statistical and Data Management Center (SDMC) for the AIDS Clinical Trials Group (ACTG), funded by the National Institutes of Health. Dr. Hughes' research program focuses on statistical methods related to the design and analysis of clinical trials and observational studies, particularly in the context of HIV research. He is well-known for his work on the development of methods for evaluating surrogate markers using meta-analysis of results from multiple clinical trials, with an important early application being the assessment of CD4 cell counts and viral load as surrogate markers for AIDS development. His statistical research is strongly motivated by problems encountered in collaborative HIV research, with ongoing interests including the design and analysis of phase I/II clinical trials, bridging trials between populations, and statistical methods for diagnostic and biomarker evaluation. His work on dose-finding studies is particularly notable, including research to identify drug doses that maximize treatment success (both safety and efficacy) rather than just finding maximal tolerated doses, and methodology for dose-finding in special populations like infants and pregnant women. Much of his biomarker research is motivated by the need to identify less expensive and more accessible technologies for resource-limited countries. Dr. Hughes has led major research initiatives through multiple NIH grants, including the current UM1AI068634 grant running until 2027 for the Statistical and Data Management Center of the ACTG. His recent publication record shows a strong dual focus on HIV research and COVID-19 pandemic response, with significant contributions to platform trial design (such as the ACTIV-2 trial), viral kinetics, and treatment resistance studies. His work bridges biostatistics methodology with practical clinical applications in infectious disease treatment. As Principal Investigator of the Statistical and Data Management Center for the AIDS Clinical Trials Group, Dr. Hughes leads a substantial research team that undertakes numerous studies of HIV interventions globally, including research on co-infections like tuberculosis and hepatitis. His team collaborates extensively on international health research addressing HIV treatment challenges across diverse populations and resource-limited settings.

• Blood Flow Restriction Exercise
• Musculoskeletal Health
• Chronic Pain Management
• +4 more

Associate Professor Matthew Clarkson serves as the Deputy Associate Dean for Learning and Teaching in the College of Sport, Health and Engineering at Victoria University. He is also the course chair for the Master of Clinical Exercise Science and Rehabilitation (AMEP) program, where he teaches foundational units including SCL6003 Introduction to Clinical Exercise Physiology, SCL6104 Clinical Exercise Practice, and SCL6202 Exercise Assessments and Interventions for Musculoskeletal Conditions. Additionally, he convenes units such as SCL6004 Pain Science, SCL7001 Minor Thesis, SCL7007 Exercise Physiology Practicum 1, and SCL7008 Clinical Exercise Physiology Capstone. Dr. Clarkson holds a PhD in Clinical Exercise Science from Deakin University (2019), a Master of Clinical Exercise Physiology (2012), a Bachelor of Exercise & Sports Science (Honours) (2014), and a dual Bachelor's degree in Exercise & Sports Science and Commerce (Sport Management) (2010), all from Deakin University. He also completed a Graduate Certificate in Tertiary Education from Victoria University. As an accredited exercise physiologist with over 17 years of industry experience, Dr. Clarkson's research focuses on pragmatic exercise solutions for performance and rehabilitation. His primary research areas include blood flow restriction exercise (methodology and clinical applications) and individualizing exercise prescription for patients with clinical conditions, particularly chronic pain and chronic kidney disease. He is an active member of the National Pain Special Interest Group exploring strategies for chronic pain management by exercise professionals and the Global Renal Exercise Network who research and advocate for the engagement of renal patients in physical activity. Dr. Clarkson's recent publications demonstrate a strong focus on blood flow restriction exercise methodologies, applications for chronic conditions, and innovative approaches to managing chronic low back pain through running interventions (the ASTEROID trials). His work spans systematic reviews, clinical trials, and methodological examinations of exercise interventions, with a particular emphasis on translating research findings into practical clinical applications. Dr. Clarkson has made significant contributions to his field through professional service, including: Course accreditation reviewer for Exercise and Sports Science Australia (ESSA) Deputy chair/member of ESSA review committees for Accredited Exercise Physiologist and Accredited Exercise Scientist professional standards Director for the Council of Heads of Exercise, Sport, and Movement Sciences (CHESMS) Member of the ESSA Victorian state chapter committee With extensive experience supervising research students, Dr. Clarkson has guided 1 PhD student, 9 Masters students, and 2 Honours students through projects focused on blood flow restriction exercise, exercise for chronic pain, and adherence to home-based exercise programs. His collaborative approach extends to building partnerships across healthcare provision and research, with a particular focus on advancing the role of exercise professionals within Australia's allied health workforce.

Andrew RundleView profile

Professor

• Built Environment and Health
• Obesity and Sedentary Lifestyles
• Neighborhood Effects on Health
• +7 more

Andrew Rundle is a Professor of Epidemiology at Columbia University's Mailman School of Public Health, where he directs the Built Environment and Health Research Group. He holds affiliations with the Health Analytics and Smart Cities centers, bridging public health, urban planning, and data science to address community health challenges through trans-disciplinary research. Dr. Rundle's research centers on neighborhood built, economic, and social environments as determinants of health behaviors and outcomes, with primary focus on obesity, sedentary lifestyles, and energy balance. His work extends to childhood neurodevelopment, asthma, pedestrian injuries, cancer survivorship, and elderly mental health. He has directly influenced urban policy through contributions to New York City's Active Design Guidelines, the FRESH food retail initiative, and the WELL Building certification program, demonstrating real-world application of epidemiological findings. His recent publications (2024-2025) reveal strong methodological innovation in spatial epidemiology and big data analytics, with recurring themes in neighborhood walkability-physical activity relationships, environmental health disparities, and cancer outcome inequities. Key approaches include geospatial modeling, electronic health record analysis, and Google Street View-based environmental assessments, reflecting his expertise in translating complex data into actionable public health insights. Scientific Awards: None explicitly mentioned in the provided information. Dr. Rundle maintains extensive industry partnerships with organizations including Schlumberger, BMW, Delos Living, and Fidelity Investments, focusing on employee health optimization, medical cost reduction, and data analytics capacity building. These collaborations involve product development, research strategy, and business analytics, demonstrating his ability to bridge academic research with corporate health initiatives through sophisticated analysis of medical claims and administrative datasets. He leads the Built Environment and Health Research Group, which employs innovative trans-disciplinary methods including GIS mapping, street view assessments, and spatial statistics to investigate how neighborhood characteristics shape health outcomes. The group's work directly informs urban policy frameworks and has established foundational evidence for built environment interventions targeting obesity and chronic disease prevention in diverse populations.

Stephan Maximilian Herbert RöhrlView profile

Professor

• Orthopaedic Surgery
• Biomechanics
• Radiostereometric Analysis
• +4 more

Stephan Maximilian Herbert Röhrl is a Professor at the Department of Orthopaedics within the Faculty of Medicine at the University of Oslo. He maintains his clinical and research activities at Ullevål University Hospital (OUS, Ullevål) and is a key member of CIRRO (Center for Implant and Related Research Oslo). His work bridges clinical orthopaedic practice with advanced biomechanical research methodologies. Professor Röhrl's research interests span orthopaedic biomechanics, radiostereometric analysis (RSA), joint replacement techniques, and orthopaedic implant evaluation. His work particularly focuses on precise measurement of implant migration, wear analysis, and biomechanical testing of new surgical techniques and devices. He has made significant contributions to understanding hip and knee arthroplasty outcomes, fracture management techniques, and sacroiliac joint procedures through rigorous biomechanical and clinical studies. His publication record reveals a clear trajectory of increasingly sophisticated imaging techniques applied to orthopaedic research. Starting with traditional RSA methods, his recent work has pioneered CT-based RSA approaches that offer greater precision in measuring implant migration and wear. His research consistently addresses clinically relevant questions about implant stability, surgical techniques, and patient outcomes across various orthopaedic subspecialties including hip, knee, wrist, and foot/ankle surgery. Professor Röhrl maintains an active collaboration network across Norwegian orthopaedic research centers and participates in numerous multi-center clinical trials. His work with the Norwegian Arthroplasty Register demonstrates his commitment to population-level orthopaedic outcomes research. As a principal investigator at CIRRO, he leads research efforts focused on improving the precision of implant evaluation techniques and translating biomechanical findings into clinical practice. His laboratory work with cadaveric models and advanced imaging provides crucial preclinical data for new orthopaedic devices and techniques.

Samuel ArnoldView profile

Assistant Professor

• Infectious Diseases
• Pharmacokinetics-Pharmacodynamics
• Drug Discovery
• +7 more

Dr. Samuel Arnold is an Assistant Professor in the Department of Pharmaceutics at the University of Washington School of Pharmacy, where he joined in 2023. His research focuses on characterizing exposure-response relationships for therapeutic treatment of infectious diarrhea, particularly for pathogens like Cryptosporidium and Shigella. As a member of the Bill & Melinda Gates Foundation Cryptosporidium Drug Accelerator (CryptoDA), Dr. Arnold has led significant efforts to identify pharmacokinetic/pharmacodynamic relationships for anti-cryptosporidiosis drugs. Dr. Arnold earned his Bachelor of Science in Biochemistry from the University of Colorado and his Ph.D. in Pharmaceutics from the University of Washington. His research interests center on infectious diseases, particularly pharmacokinetic-pharmacodynamic modeling for treatment of enteric infections, enteric disease induced changes in drug disposition, and improved preclinical models of drug disposition in the gastrointestinal tract. His expertise spans drug discovery, in vitro to in vivo extrapolation, intestinal surgery and GI diseases, microphysiological organ systems, pharmacokinetics-pharmacodynamics, pharmacology, simulation modeling, and translational research. Dr. Arnold's publication record demonstrates significant contributions to the understanding of diarrheal diseases and their impact on drug pharmacokinetics. His work shows a clear progression from foundational studies on parasitic infections to clinical applications, with a strong emphasis on translational research that bridges laboratory findings with clinical practice. Recent publications highlight his focus on physiologically based pharmacokinetic modeling to predict how diarrheal diseases affect oral drug pharmacokinetics, as well as ongoing clinical investigations into novel treatments for shigellosis and cryptosporidiosis. Dr. Arnold actively participates in collaborative research initiatives, including clinical trials investigating clofazimine as a potential anti-cryptosporidiosis treatment (Clinicaltrials.gov #NCT03341767). His lab is working on developing pharmacokinetic models that can predict the impact of diarrhea on drug exposure prior to human dosing, which represents a significant advancement in the field of infectious disease pharmacology. Dr. Arnold accepts students to his laboratory and teaches courses PCEUT531, PCEUT532, and PCEUT506 at the University of Washington School of Pharmacy. His research has important implications for global health, as diarrheal diseases remain the second leading cause of death in children under five years old worldwide.

• Evidence-Based Medicine
• Clinical Guideline Development
• GRADE Methodology
• +4 more

Reem Adel Mustafa serves as a Part-Time Associate Professor in the Health Research Methods, Evidence, and Impact department within McMaster University's Faculty of Health Sciences . Her academic appointment reflects deep engagement with evidence-based medicine and clinical guideline development. Research Interests: Dr. Mustafa specializes in GRADE methodology for evidence assessment, with significant contributions to nephrology (particularly autosomal dominant polycystic kidney disease), hematology (venous thromboembolism, von Willebrand disease), and health equity integration in guidelines. Her work bridges methodological rigor with clinical application across multiple disease domains. Publications Trend: Recent output (2023-2025) shows dominance in living guideline development (e.g., diabetes therapeutics, lupus nephritis), GRADE framework extensions (41+ guidance papers), and international registry analyses (ADPKD, VTE). Over 75% of publications involve multi-society guideline panels (ACR, ASH, ISTH, KDIGO). Professional Engagement: She actively contributes to major guideline initiatives including KDIGO 2025 ADPKD guidelines, ACR lupus nephritis guidelines, and ASH/ISTH pediatric VTE guidelines. Her methodological work focuses on improving evidence-to-decision frameworks and addressing health equity gaps in guideline development.

Sally CliveView profile

Senior Lecturer

• Colorectal Cancer
• Cancers of Unknown Primary
• Clinical Trials
• +2 more

Dr. Sally Clive is a Consultant Medical Oncologist at the Edinburgh Cancer Centre and NHS Fife, and an Honorary Senior Lecturer affiliated with the University of Edinburgh. She specializes in colorectal cancer, cancers of unknown primary (CUP), clinical trials, cancer medicine governance, and health technology appraisal. Her work is supported by an NRS Career Researcher Award (2012-present). Her research focuses on optimizing patient pathways and clinical outcomes in colorectal cancer and CUP. Key interests include prognostic biomarker development, systemic inflammation in cancer progression, pragmatic clinical trial designs for vulnerable populations, and health service innovations for diagnostic challenges. Dr. Clive's publications demonstrate consistent contributions to oncology trial methodology, biomarker validation, and therapeutic optimization, with recent emphasis on inflammation-based prognostication and real-world clinical pathway analysis. Scientific Awards: NRS Career Researcher Award (2012-present) She leads a multidisciplinary research group collaborating across Edinburgh Cancer Centre and NHS Fife, including co-investigators in colorectal trials (Drs. Brown, Dawson, Yan, McNair, Robertson), CUP research (Drs. Barrie, Stares), data management (Mr. McPherson), and clinical nursing leadership (Ms. McVicars).

Jane GreatorexView profile

Professor

• Virology
• Blood Borne Viruses
• HIV Diagnostics
• +7 more

Jane Greatorex serves as Senior Tutor, Undergraduate and Graduate Tutor, and Director of Studies in Pre-Clinical Medical and Veterinary Sciences at Lucy Cavendish College, University of Cambridge. She holds a PhD from the Open University and maintains active roles across the university's School of Clinical Medicine and Department of Veterinary Medicine. Her research spans critical virology domains including blood-borne viruses, HIV diagnostics, Ebola outbreak response, and influenza transmission dynamics. Greatorex specializes in next-generation sequencing applications for identifying resistance mutations in HIV and human herpes viruses, alongside investigating H1N1 influenza shedding and survival. Her work bridges laboratory research with real-world pandemic response, having led teams during the 2015 Ebola outbreak in Sierra Leone and contributing to national policy discussions during the COVID-19 pandemic. Analysis of her recent publications reveals strong focus on viral transmission mechanisms, diagnostic innovation, and infection control. Her work spans laboratory virology, clinical epidemiology, and public health implementation, with consistent emphasis on practical applications for outbreak management and pandemic preparedness. Key trends include molecular characterization of viral resistance, environmental virus survival, and real-world transmission dynamics. Greatorex plays significant institutional roles beyond research: she oversees student admission, education, and welfare at Lucy Cavendish College; recruits Junior Research Fellows and Post-doctoral Research Associates; lectures Masters students; and supervises undergraduate projects. Her leadership extends to high-containment laboratory operations and emergency response teams, maintaining readiness for future viral outbreaks through her placement on national scientist response lists.